Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...979899100101102103104105106107...858859»
  • ||||||||||  FDA event, Journal:  An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021). (Pubmed Central) -  Jan 30, 2024   
    The review comprises the key structural features, approval times, target selectivity, mechanisms of action, therapeutic indication, formulations, and possible synthetic approaches of these approved drugs. These crucial details will benefit the scientific community for futuristic new developments in this arena.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Review, Journal:  Blinatumomab in Practice. (Pubmed Central) -  Jan 30, 2024   
    When care is coordinated in these settings, serious side effects can be recognized early, allowing for necessary intervention leading to improved quality of life and overall survival. Future research will continue to evaluate blinatumomab in different lines of therapy and expand its way into community settings.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), omecamtiv mecarbil (AMG 423) / Amgen, Servier, Kerendia (finerenone) / Bayer
    Journal:  Pharmacological Treatment of Heart Failure: Recent Advances. (Pubmed Central) -  Jan 29, 2024   
    Individualized heart failure therapy research have shown some benefit in select heart failure patients. Further research on novel therapies will help improve heart failure patient outcomes.
  • ||||||||||  ivabradine / Generic mfg.
    Retrospective data, Journal:  Evaluating the applicability of ivabradine in acute heart failure. (Pubmed Central) -  Jan 29, 2024   
    For hospitalized acute decompensated heart failure patients who are intolerant to ?-blockers or cannot further titrate them, ivabradine offers a consistent therapeutic effect. No significant disparities were noted between the ivabradine and non-ivabradine groups in heart failure hospitalization and cardiovascular death.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, ME-344 / MEI
    Preclinical, Journal:  Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro. (Pubmed Central) -  Jan 29, 2024   
    Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) in patients who are over the age of 75 or cannot tolerate standard chemotherapy...Further, lometrexol, a purine biosynthesis inhibitor, synergistically enhanced VEN-induced apoptosis in AML cell lines...In vivo studies revealed significantly prolonged survival upon combination therapy of ME-344 and VEN in NSGS mice bearing parental or AraC-resistant MV4-11 leukemia compared to the vehicle control. This study demonstrates that ME-344 enhances VEN antileukemic activity against preclinical models of AML by suppressing OXPHOS and/or purine biosynthesis.
  • ||||||||||  Journal:  PCSK9-directed therapies: an update. (Pubmed Central) -  Jan 26, 2024   
    Long-term inhibition of PCSK9 with monoclonal antibodies is safe and conveys sustained cardiovascular benefit. Novel strategies to inhibit PCSK9 function such as orally available drugs, RNA targeting, and one-time treatment with gene editing may further enhance the therapeutic armamentarium and enable novel preventive strategies.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Co-targeting CDK4/6 and BRD4 promotes senescence and ferroptosis sensitivity in cancer. (Pubmed Central) -  Jan 26, 2024   
    Through a genome-wide cDNA screen, we identified that bromodomain-containing protein 4 (BRD4) overexpression conferred resistance to the CDK4/6 inhibitor palbociclib in KRAS-mutant NSCLC cells...Co-targeting CDK4/6 and BRD4 also promoted senescence and ferroptosis vulnerability in pancreatic and breast cancer cells. Together, these findings reveal therapeutic vulnerabilities and effective combinations to enhance the clinical utility of CDK4/6 inhibitors.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal, IO biomarker:  Immune modulation with RANKL blockade through denosumab treatment in patients with cancer. (Pubmed Central) -  Jan 26, 2024   
    We also saw broad induction of CTLA-4 and TIM3 expression in circulating lymphocytes and some monocyte populations. These findings suggest that denosumab treatment by itself has modest immunomodulatory effects, but when combined with conventional cancer treatments, can lead to the induction of immunologic checkpoints.
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    Journal:  Identification of a New Integration Site and Study on Site-Specific Integration in CHO-K1 Cells. (Pubmed Central) -  Jan 26, 2024   
    We performed a passaged stability study on SSI-4 and proved the possibility of the stable, site-specific integration of exogenous genes at this locus in terms of integration site, copy number, expression level, and cell growth. In summary, our study has identified a new integration site suitable for site-specific integration, which lays the foundation for the subsequent development of site-specific integration cell lines.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Verzenio (abemaciclib) / Eli Lilly
    Observational data, Retrospective data, Journal:  Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer. (Pubmed Central) -  Jan 26, 2024   
    The differences were statistically significant in the patients who used abemaciclib. Given that the use of this combination is very common in routine clinical practice, it would be advisable to carry out larger prospective studies to clarify the risk of this association.
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas
    EVOLOCUMAB-INDUCED PARADOXICAL RISE OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LEVELS (Moderated Poster Theater 10) -  Jan 26, 2024 - Abstract #ACC2024ACC_7000;    
    To our knowledge, this is the first report of a paradoxical rise in LDL-C following evolocumab use. Yet, the explanation needs to be further investigated for possible pathophysiologic and biochemical mechanisms, as it has significant clinical implications.
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas
    SEVERE CORONARY ARTERY DISEASE LEADING TO CARDIAC ARREST IN AN ELITE ATHLETE (Hall B4-5) -  Jan 26, 2024 - Abstract #ACC2024ACC_6774;    
    While young age and high physical activity typically portend lower risk of impending MI, hyperlipidemia in those with MODY3 must be treated aggressively. Some case reports suggest an association between MODY3 and CAD out of proportion to the severity of diabetes, possibly due to concurrent effects on lipid metabolism and inflammation.
  • ||||||||||  NAVIGATING THE CHALLENGES OF TURNER SYNDROME WITH TYPE B AORTIC DISSECTION (Hall B4-5) -  Jan 26, 2024 - Abstract #ACC2024ACC_5770;    
    Maintain a high index of suspicion for aortic dissection in Turner Syndrome patients with chest pain. Imaging is crucial for guiding management decisions and surveillance of Turner syndrome patients with Type B aortic dissection.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, Mvasi (bevacizumab-awwb) / Daiichi Sankyo, Amgen, AbbVie
    ONE BATTLE AFTER ANOTHER: BEVACIZUMAB CARDIOMYOPATHY AFTER HIGH-GRADE ENDOMETRIAL CARCINOMA (Hall B4-5) -  Jan 26, 2024 - Abstract #ACC2024ACC_4920;    
    Around 2-4% of bevacizumab-treated patients develop cardiomyopathy and heart failure. Bevacizumab biosimilar cardiotoxicity data are limited.
  • ||||||||||  Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    LABORATORY AND FUNCTIONAL MONITORING IN A PATIENT WITH CHRONIC MYOCARDITIS POST-COVID-19: CASE REPORT (Hall B4-5) -  Jan 26, 2024 - Abstract #ACC2024ACC_4875;    
    Laboratory findings, such as elevated troponin and BNP, have been observed in cases of COVID-19-associated myocarditis and, in this case, correlated with cardiac functional findings, such as EF. The significance of this correlation is uncertain, but it may provide data for the diagnosis and monitoring reverse remodeling of post-COVID-19 DCM in the future.
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas
    COMPLEX LIPID MANAGEMENT: EXTREME HYPERABSORBER PHYSIOLOGY IN A PATIENT WITH CLINICAL FAMILIAL HYPERCHOLESTEROLEMIA (Moderated Poster Theater 12) -  Jan 26, 2024 - Abstract #ACC2024ACC_4838;    
    Patients with clinically diagnosed familial hypercholesterolemia and suboptimal responses to statin therapies or PCSK9 inhibition may demonstrate a hyperabsorber phenotype that responds disproportionately well to ezetimibe therapy. Ezetimibe should be considered in FH treatment regardless of responses to other lipid lowering therapies.
  • ||||||||||  clopidogrel / Generic mfg.
    STEVENS-JOHNSON SYNDROME SECONDARY TO CLOPIDOGREL USE (Hall B4-5) -  Jan 26, 2024 - Abstract #ACC2024ACC_2144;    
    The syndrome develops within days to weeks of starting the offending drug. Clopidogrel is a rare cause of this severe hypersensitivity reaction.
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas, TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
    TWO HITS: STEMI IN ELEVATED LIPOPROTEIN (A) AND JAK2 MUTATION (Hall B4-5) -  Jan 26, 2024 - Abstract #ACC2024ACC_1674;    
    Further investigation with genetic testing and/or polygenic risk score may reveal underlying etiology of coronary artery disease (CAD). PCI should be considered in patients with chest pain suspected to have genetic risk factors for CAD with use of further imaging such as IVUS or optical coherence tomography to confirm high risk lesions.